{
    "clinical_study": {
        "@rank": "78997", 
        "arm_group": {
            "arm_group_label": "Bone mets"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer\n      that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start\n      of new breast cancer hormone treatment and again at 12 weeks after treatment start. The\n      baseline uptake and change in uptake after the repeat scans will be compared to clinical\n      long term outcomes such as time to progression and overall survival. In addition the uptake\n      will be compared to the incidence of skeletal related events that are common occurrences in\n      patients with cancer that has spread to the bones."
        }, 
        "brief_title": "FDG PET/CT in Breast Cancer Bone Mets", 
        "condition": [
            "Estrogen Receptor Positive Breast Cancer", 
            "Bone Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Bone Neoplasms", 
                "Bone Marrow Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an observational study as all patients will receive the same research diagnostic\n      test, an FDG PET/CT study performed at 4 weeks after starting new hormone treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult patients, at least 18 years of age, with a history of pathologically confirmed\n             ER+ breast cancer\n\n          2. Biopsy proven or clinically obvious documented bone metastases from breast cancer\n             (with the majority of the disease burden in the bone)\n\n          3. Patients planning  to start new endocrine targeted therapy (any line of therapy is\n             acceptable and any endocrine therapy is allowed)\n\n          4. Willing and able to comply with scheduled visits and serial imaging procedures\n\n          5. Agrees to allow access to clinical records regarding response to treatment and long\n             term follow up.\n\n          6. Be informed of the investigational nature of this study and provide written informed\n             consent in accordance with institutional and federal guidelines\n\n        Exclusion Criteria:\n\n          1. Women who are pregnant or breast feeding\n\n          2. Uncontrolled diabetes mellitus (fasting glucose greater than 200 mg/dL)\n\n          3. Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)\n\n          4. Weight exceeding capacity of imaging table\n\n          5. Previous treatment with radiation or surgery to a significant percentage of bony\n             metastatic sites\n\n          6. Treatment with marrow stimulating agents (e.g. granulocyte colony stimulating factor\n             (GCSF)) within 3 weeks of baseline scan"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with a history of ER+ breast cancer with documented bone metastases from\n        breast cancer. Patients must be planning to start new hormone therapy for their breast\n        cancer."
            }
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996046", 
            "org_study_id": "817940", 
            "secondary_id": "UPCC17113"
        }, 
        "intervention": {
            "arm_group_label": "Bone mets", 
            "intervention_name": "FDG PET/CT scan", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania Hospital"
            }, 
            "investigator": {
                "last_name": "David Mankoff, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer", 
        "other_outcome": {
            "description": "Occurrence of radiation therapy to stabilize skeletal disease, pathologic fracture,spinal cord compression, surgery to stabilize the skeleton or hypercalcemia of malignancy will be recorded", 
            "measure": "Number of patients who have a Skeletal Related Event", 
            "safety_issue": "No", 
            "time_frame": "medical record reviewed every 6 months from date of enrollment to date of death, up to 120 months"
        }, 
        "overall_contact": {
            "email": "erin.schubert@uphs.upenn.edu", 
            "last_name": "Erin Schubert", 
            "phone": "215-898-0191"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Date of clinical progression will be recorded", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "medical record reviewed every 6 months from date of enrollment to date of progression, up to 120 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996046"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "David Mankoff", 
            "investigator_title": "Professor of radiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Date of death will be recorded", 
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "medical record reviewed every 6 months from date of enrollment to date of death, up to 120 months"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}